NUCLEOSIDE INHIBITORS OF RHODOPSIN KINASE

被引:33
|
作者
PALCZEWSKI, K
KAHN, N
HARGRAVE, PA
机构
[1] UNIV FLORIDA,DEPT OPHTHALMOL,GAINESVILLE,FL 32611
[2] UNIV FLORIDA,DEPT BIOCHEM & MOLEC BIOL,GAINESVILLE,FL 32611
[3] SO ILLINOIS UNIV,SCH MED,DEPT MED BIOCHEM,SPRINGFIELD,IL 62708
关键词
D O I
10.1021/bi00478a024
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The specificity of the ATP-binding site of rhodopsin kinase was studied with adenosine analogues that are competitive inhibitors. Systematic changes in the ribose ring (position 5′) and the purine ring (positions 2, 6, 7, 8, and 9) and determination of the inhibitory properties of these analogues lead to the following conclusions: (1) The N6 nitrogen in the purine ring is essential for binding at the active site, which may explain the marked preference for ATP rather than GTP as substrate. (2) The configuration of the sugar moiety is critical for the binding. (3) Positions 2, 3, and 8 of the purine ring, as well as the polyphosphate chain, play a minor role in substrate recognition by rhodopsin kinase. (4) ATPYS is a good substrate for rhodopsin kinase (thus rhodopsin phosphorothioate, a phosphatase-resistant product, can be formed in order to study the role of phosphorylation in rod outer segments). Pyrrolopyrimidine derivatives are very potent inhibitors of rhodopsin kinase. The Ki of one of these, sangivamycin, is 180 nM. Sangivamycin in solution assumes the anti conformation, as determined by nuclear Overhauser measurement. These measurements show that the most potent inhibitors of rhodopsin kinase, sangivamycin and toyocamycin, occur in solution preferentially in the anti conformation. Many nucleotides and nucleosides tested that are not inhibitors are syn, and many that are inhibitors form a mixture of syn and anti. The hypothesis that inhibitors may have a conformation intermediate between syn and anti was strengthened by testing a cyclic nucleoside locked in an anti conformation. This compound, an 8,3′-cycloadenosine derivative, is a good inhibitor of rhodopsin kinase with Ki = 10 µM. This suggests that rhodopsin kinase binds nucleosides in an intermediate syn/anti conformation. The low Ki value for sangivamycin allows us to block phosphorylation in whole rod outer segments with submicromolar concentrations, lower than those required for blocking other protein kinases. © 1990, American Chemical Society. All rights reserved.
引用
收藏
页码:6276 / 6282
页数:7
相关论文
共 50 条
  • [1] Inhibition of nucleoside transport by protein kinase inhibitors
    Huang, M
    Wang, YH
    Cogut, SB
    Mitchell, BS
    Graves, LM
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2003, 304 (02): : 753 - 760
  • [2] Regulation of equilibrative nucleoside uptake by protein kinase inhibitors
    Huang, M
    Wang, YH
    Mitchell, BS
    Graves, LM
    NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS, 2004, 23 (8-9): : 1445 - 1450
  • [3] SAR of a series of nucleoside analogs as adenosine kinase inhibitors
    Cowart, M
    Bennett, MJ
    Gfesser, G
    Bhagwat, SS
    Kohlhaas, KL
    Alexander, KM
    Zhu, C
    Britton, D
    Lynch, J
    Yu, H
    Gunther, K
    Kerwin, JF
    Kowaluk, EA
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1997, 213 : 173 - MEDI
  • [4] RHODOPSIN KINASE
    SHICHI, H
    SOMERS, RL
    YAMAMOTO, K
    METHODS IN ENZYMOLOGY, 1983, 99 : 362 - 366
  • [5] Interaction of multitargeted tyrosine kinase inhibitors with human nucleoside transporters
    Damaraju, Vijaya L.
    Kuzma, Michelle
    Mowles, Delores
    Cass, Carol E.
    Sawyer, Michael B.
    CANCER RESEARCH, 2014, 74 (19)
  • [6] Discovery of novel non-nucleoside adenosine kinase inhibitors
    Koese, Meryem
    Fischer, Julia
    Tan, Lu
    Bajorath, Juergen
    Stachel, Hans-Dietrich
    Poschenrieder, Hermann
    Schiedel, Anke C.
    Mueller, Christa E.
    PURINERGIC SIGNALLING, 2008, 4 : S61 - S61
  • [7] RGD mutants and inhibitors for human nucleoside diphosphate kinase A.
    Yeh, AYC
    Yeh, HW
    FASEB JOURNAL, 1997, 11 (03): : 3130 - 3130
  • [8] Nucleoside transporter subtype expression:: effects on potency of adenosine kinase inhibitors
    Sinclair, CJD
    Powell, AE
    Xiong, W
    LaRivière, CG
    Baldwin, SA
    Cass, CE
    Young, JD
    Parkinson, FE
    BRITISH JOURNAL OF PHARMACOLOGY, 2001, 134 (05) : 1037 - 1044
  • [9] Exploring acyclic nucleoside analogues as inhibitors of Mycobacterium tuberculosis thymidylate kinase
    Familiar, Olga
    Munier-Lehmann, Helene
    Negri, Ana
    Gago, Federico
    Douguet, Dominique
    Rigouts, Leen
    Hernandez, Ana-Isabel
    Camarasa, Maria-Jose
    Perez-Perez, Maria-Jesus
    CHEMMEDCHEM, 2008, 3 (07) : 1083 - 1093
  • [10] Acyclic nucleoside analogues as novel inhibitors of human mitochondrial thymidine kinase
    Hernández, AI
    Balzarini, J
    Karlsson, A
    Camarasa, MJ
    Pérez-Pérez, MJ
    JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (19) : 4254 - 4263